{"brief_title": "A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention", "brief_summary": "The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.", "condition": "Acute Coronary Syndromes", "intervention_type": "Drug", "intervention_name": "Clopidogrel", "description": "Administered orally", "arm_group_label": "Clopidogrel", "other_name": "Efient", "criteria": "Inclusion Criteria: - A person who has been diagnosed with acute coronary syndrome and is to undergo a percutaneous coronary intervention. - A person who is of the legal age of 18 and is mentally competent to provide a signed written informed consent. - If a woman is of childbearing potential (i.e., before menopause), she must test negative for pregnancy and agree to use a reliable method of birth control. Exclusion Criteria: - A person who has had an ischemic stroke within the last 3 months or a hemorrhagic stroke at any time in the past. - A person who has active internal bleeding or has a history of a bleeding disorder. - Individuals who are at an increased risk of bleeding based on laboratory criteria evaluated by the treatment physician or on medication that can cause bleeding. - A person who has liver disease; for example, cirrhosis. - A person who has a condition such as alcoholism, mental illness, or is drug dependent. - A person who has cardiogenic shock, a refractory ventricular arrhythmia, or congestive heart failure (class IV).", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00097591.xml"}